3D PDX-derived Cell Based Screen

Rapid translational *ex vivo* screening platform.

The 3D PDX-derived Cell Based Screen combines the relevance and translatability of PDX models with the faster turnaround times and higher throughput associated with in vitro screening applications. With cell lines established from ex vivo PDX samples, you can reliably and seamlessly make decisions with in vitro/in vivo matched models.

- Thoroughly evaluate anticancer agents through screening, characterization, PK/PD experiments, MoA studies, etc

- Conduct large-scale compound screening quickly and cost effectively

- Optimize translational research efforts:
  - Use as *ex vivo* surrogate for PDX models
  - Validate 2D model results
  - Use matched PDX models to validate 3D PDX screen results

- Guide your preclinical development strategies such ascombination strategies, dosing, 1st line vs 2nd line

Enable informed decision-making on lead candidates and patient selection, while reducing cost and project timelines:

- Clinically relevant cells derived from low passage, highly characterized PDX models

- Fast and efficient *ex vivo* screening platform

- Matched to *in vivo* and *in vitro* formats to optimize translational research efforts

3D PDX Screen Model Schematic

PDX → Dissociated PDX cells → Frozen PDX cells → 7-day compound testing → Ex vivo 3D assay (Methylcellulose, soft agar)

Correlation of 3D PDX Screen to *In Vivo* PDX Models

In vivo TGI and 3D PDX Screen data comparison for the same PDX models with matched treatments

Get in touch

Sales
US: +1 858 622 2900   busdev@crownbio.com
UK: +44 870 166 6234   www.crownbio.com

Science
consultation@crownbio.com